AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26234693 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-CD ulcerated surface
Number of subjects: 25
Study 26234693 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-CD affected surface
Number of subjects: 25
Study 26234693 — intervention group
Group type: EXPERIMENTAL
Intervention: CDEIS and SES-CD total scores
Number of subjects: 25
Study 26234693 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-CD
Number of subjects: 25
Study 26235360 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office fluoride application recommended to patients aged 6-18 years
Number of subjects: 282
Study 26235360 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office fluoride application recommended to patients aged over 18 years
Number of subjects: 282
Study 26235360 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with recommending in-office fluoride
Number of subjects: 282
Study 26235450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (including vitamin K antagonists and non-vitamin K oral anticoagulants)
Number of subjects: 1425
Study 26235450 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant-associated intracerebral hemorrhage
Number of subjects: 1425
Study 26235450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 1425
Study 26235613 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen/Esomeprazole (NAP/ESO) 500 mg/20 mg given twice daily
Number of subjects: 1219
Study 26235613 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (CEL) 200 mg given once daily
Number of subjects: 1219
Study 26235613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1219
Study 26235848 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (n=48)
Number of subjects: 73
Study 26235848 — intervention group
Group type: COMPARATOR
Intervention: No radiation (n=25)
Number of subjects: 73
Study 26236506 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β-1a 44 μg or 22 μg subcutaneously three times weekly
Number of subjects: 334
Study 26237266 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires of auditory difficulties
Number of subjects: 99
Study 26237266 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based tests
Number of subjects: 99
Study 26237266 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments of speech understanding in noise, binaural processing, temporal resolution, and speech segregation
Number of subjects: 99
Study 26237266 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance on 10 measures
Number of subjects: 99
Study 26237356 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-week physical training program
Number of subjects: 18
Study 26237773 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated OSA
Number of subjects: 35
Study 26237773 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 26238198 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraph-GT3X+ accelerometer measuring counts-per-minute (CPM) for physical activity intensity assessment
Number of subjects: 111
Study 26238198 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-regression-model analysis of VO2max percentage and gender
Number of subjects: 111
Study 26238198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector-magnitude (VM) model
Number of subjects: 111
Study 26238730 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced group (master/associate master faculty)
Number of subjects: 22
Study 26238730 — intervention group
Group type: COMPARATOR
Intervention: Novice group (postgraduate year 4 and 5 residents)
Number of subjects: 22
Study 26238730 — intervention group
Group type: COMPARATOR
Intervention: Novice group
Number of subjects: 22
Study 26238730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 26238730 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced group
Number of subjects: 22
Study 26238761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D)
Number of subjects: 50
Study 26238761 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia (C)
Number of subjects: 50
Study 26238974 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of disease targets (SDAI ≤3.3)
Number of subjects: 1297
Study 26238974 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of disease targets (CDAI ≤2.8)
Number of subjects: 1297
Study 26238974 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of disease targets (DAS28-CRP <2.6)
Number of subjects: 1297
Study 26238974 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of disease targets
Number of subjects: 1297
Study 26239690 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent antipsychotic medications (including 40 mg pimavanserin daily)
Number of subjects: 459
Study 26239690 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent antipsychotic medications
Number of subjects: 459
Study 26240075 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (intermittent walking to mild-to-moderate claudication pain for 3 months)
Number of subjects: 46
Study 26241603 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for Partner Violence
Number of subjects: 0
Study 26241603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study 26241763 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe CPSP (NRS ≥3/10) at 12 months
Number of subjects: 3120
Study 26241763 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pain (NRS ≥6) at 12 months
Number of subjects: 3120
Study 26241763 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs of neuropathic pain in patients with moderate CPSP
Number of subjects: 3120
Study 26241763 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs of neuropathic pain in patients with severe CPSP
Number of subjects: 3120
Study 26241763 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional impairment (BPI) at 6 and 12 months
Number of subjects: 3120
Study 26241763 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for CPSP
Number of subjects: 3120
Study 26241763 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of time in severe pain on D1
Number of subjects: 3120
Study 26242184 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist (GLP-1RA) therapy
Number of subjects: 620
Study 26242184 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1RA therapy
Number of subjects: 620
Study 26242577 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depression Inventory (MDI)
Number of subjects: 0
Study 26242577 — intervention group
Group type: COMPARATOR
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 0
Study 26242713 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) pre-PCI
Number of subjects: 418
Study 26242713 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) post-PCI
Number of subjects: 418
Study 26242713 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI FFR values
Number of subjects: 418
Study 26242713 — intervention group
Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events (MACE) at 30 days
Number of subjects: 418
Study 26242713 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician decision-making influenced by OCT
Number of subjects: 418
Study 26242794 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of depression as measured by the Montgomery and Asberg Depression Rating Scale (MADRS)
Number of subjects: 145
Study 26242794 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual MADRS items during treatment
Number of subjects: 145
Study 26242794 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of depression
Number of subjects: 145
Study 26242981 — intervention group
Group type: COMPARATOR
Intervention: Intravenous adenosine infusion (140-175mcg/kg/min)
Number of subjects: 149
Study 26242981 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson bolus (400mcg)
Number of subjects: 149
Study 26242981 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson single-bolus administration
Number of subjects: 149
Study 26243227 — intervention group
Group type: EXPERIMENTAL
Intervention: RC-ABC (ABC/2 score calculated at a specialized reading center)
Number of subjects: 507
Study 26243227 — intervention group
Group type: EXPERIMENTAL
Intervention: site-ABC (ABC/2 score calculated at local site)
Number of subjects: 507
Study 26243227 — intervention group
Group type: EXPERIMENTAL
Intervention: RC-ABC
Number of subjects: 507
Study 26243227 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/2 scores at local or central sites
Number of subjects: 507
Study 26243260 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exacerbations of COPD (AE-COPD)
Number of subjects: 33
Study 26243788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive pregnancy
Number of subjects: 2637
Study 26243788 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnancy
Number of subjects: 2637
Study 26244136 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 0
Study 26244136 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 0
Study 26244396 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmitters (n=91)
Number of subjects: 182
Study 26244396 — intervention group
Group type: COMPARATOR
Intervention: Nontransmitters (n=91)
Number of subjects: 182
Study 26244396 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 182
Study 26244751 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 0
Study 26244832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (1.0 mg/kg once daily)
Number of subjects: 23
Study 26244883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Patients (BP)
Number of subjects: 27
Study 26244883 — intervention group
Group type: COMPARATOR
Intervention: Healthy Subjects (HS)
Number of subjects: 27
Study 26245196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 10 µL with 2,500 PfSPZ (n=6)
Number of subjects: 36
Study 26245196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 50 µL with 2,500 PfSPZ (n=6)
Number of subjects: 36
Study 26245196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 250 µL with 2,500 PfSPZ (n=6)
Number of subjects: 36
Study 26245196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 25,000 PfSPZ (n=6)
Number of subjects: 36
Study 26245196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 75,000 PfSPZ (n=6)
Number of subjects: 36
Study 26245196 — intervention group
Group type: COMPARATOR
Intervention: Direct venous inoculation of 3,200 PfSPZ (n=6)
Number of subjects: 36
Study 26245279 — intervention group
Group type: EXPERIMENTAL
Intervention: Medifast 4 & 2 & 1 Plan
Number of subjects: 310
Study 26245808 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 9
Study 26245948 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoperineal excision (APE)
Number of subjects: 545
Study 26245948 — intervention group
Group type: COMPARATOR
Intervention: Extralevator APE (ELAPE)
Number of subjects: 545
Study 26245948 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe perineal symptoms
Number of subjects: 545
Study 26246321 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (<900 kcal/d) for 6 weeks
Number of subjects: 9
Study 26246321 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (<900 kcal/d) for 12 weeks
Number of subjects: 9
Study 26246436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction
Number of subjects: 70
Study 26246845 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape extract (GE)
Number of subjects: 90
Study 26246845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 26246908 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 171
Study 26246908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 26248048 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical predictors associated with HRQoL outcomes
Number of subjects: 256
Study 26248353 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g meropenem every 8 hours as a 15-min infusion
Number of subjects: 5
Study 26248495 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-high compression stockings
Number of subjects: 47
Study 26248495 — intervention group
Group type: COMPARATOR
Intervention: No compression stockings (control)
Number of subjects: 47
Study 26248638 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 2×10 mg/kg intravenously followed by 3 mg/kg IV every 4 weeks
Number of subjects: 13
Study 26248638 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 13
Study 26248638 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 26250067 — intervention group
Group type: COMPARATOR
Intervention: Brexpiprazole (2-4 mg/day for schizophrenia)
Number of subjects: 0
Study 26250067 — intervention group
Group type: COMPARATOR
Intervention: Brexpiprazole (for relapse prevention/maintenance)
Number of subjects: 0
Study 26250067 — intervention group
Group type: COMPARATOR
Intervention: Brexpiprazole (1, 2, and 3 mg for MDD)
Number of subjects: 0
Study 26250067 — intervention group
Group type: COMPARATOR
Intervention: Brexpiprazole (for schizophrenia)
Number of subjects: 0
Study 26250067 — intervention group
Group type: COMPARATOR
Intervention: Brexpiprazole (for MDD)
Number of subjects: 0
Study 26250576 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide and rituximab
Number of subjects: 0
Study 26250700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation attempted in 92% of cases
Number of subjects: 2327
Study 26250700 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway devices used in 5% of cases
Number of subjects: 2327
Study 26250700 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-valve-mask ventilation used in 2% of cases
Number of subjects: 2327
Study 26250700 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure used in 0.2% of cases
Number of subjects: 2327
Study 26250700 — intervention group
Group type: COMPARATOR
Intervention: Cardiac arrest patients
Number of subjects: 2327
Study 26250700 — intervention group
Group type: COMPARATOR
Intervention: Non-cardiac arrest patients
Number of subjects: 2327
Study 26251048 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infected MSM
Number of subjects: 26503
Study 26251048 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infected PWID
Number of subjects: 26503
Study 26251214 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HCV E1E2 with MF59C.1 adjuvant
Number of subjects: 112
Study 26251214 — intervention group
Group type: COMPARATOR
Intervention: Mock treatment with a control peptide
Number of subjects: 112
Study 26251251 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMMPRIS medical treatment
Number of subjects: 0
Study 26251251 — intervention group
Group type: COMPARATOR
Intervention: WASID treatment
Number of subjects: 0
Study 26251251 — intervention group
Group type: COMPARATOR
Intervention: Lack of statin use at enrollment (WASID patients)
Number of subjects: 0
Study 26251251 — intervention group
Group type: COMPARATOR
Intervention: Prior infarcts in the territory of the symptomatic vessel (WASID patients)
Number of subjects: 0
Study 26251255 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels in nonsurviving patients (n=8)
Number of subjects: 561
Study 26251255 — intervention group
Group type: COMPARATOR
Intervention: Copeptin levels in surviving patients (n=151)
Number of subjects: 561
Study 26251255 — intervention group
Group type: COMPARATOR
Intervention: Comparison of copeptin levels between cerebrovascular and stroke mimic patients
Number of subjects: 561
Study 26251255 — intervention group
Group type: COMPARATOR
Intervention: Comparison of copeptin levels between vascular and nonvascular patients
Number of subjects: 561
Study 26251255 — intervention group
Group type: COMPARATOR
Intervention: Copeptin levels and time from onset to blood draw
Number of subjects: 561
Study 26251590 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valve (EBV) therapy
Number of subjects: 43
Study 26251605 — intervention group
Group type: EXPERIMENTAL
Intervention: Max%ΔBW > 5%
Number of subjects: 465
Study 26252393 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat HCl (150 mg or 450 mg) co-administered with agalsidase (0.2, 0.5, or 1.0 mg/kg)
Number of subjects: 23
Study 26252393 — intervention group
Group type: COMPARATOR
Intervention: Agalsidase (0.2, 0.5, or 1.0 mg/kg) alone
Number of subjects: 23
Study 26252852 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal insert device
Number of subjects: 91
Study 26252914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL D) patients
Number of subjects: 49
Study 26253018 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated image analysis using a sequential classification algorithm based on glandular and cellular morphology
Number of subjects: 58
Study 26253018 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated image analysis applied to an independent validation set
Number of subjects: 58
Study 26253733 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR) assessment
Number of subjects: 106
Study 26253733 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR for flow-limiting coronary artery disease (FFR≤0.8)
Number of subjects: 106
Study 26253733 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for FFR
Number of subjects: 106
Study 26254174 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral subcapsular orchiectomy
Number of subjects: 14
Study 26254174 — intervention group
Group type: COMPARATOR
Intervention: Aromatase inhibitor (letrozol, 2.5 mg/d for 3 months)
Number of subjects: 14
Study 26254174 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative testosterone levels
Number of subjects: 14
Study 26254317 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-assisted treatment (MAT)
Number of subjects: 485
Study 26254317 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential treatment
Number of subjects: 485
Study 26254317 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-free counseling
Number of subjects: 485
Study 26254317 — intervention group
Group type: EXPERIMENTAL
Intervention: NA/AA meetings only
Number of subjects: 485
Study 26254317 — intervention group
Group type: EXPERIMENTAL
Intervention: No additional treatment
Number of subjects: 485
Study 26254317 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential treatment preference
Number of subjects: 485
Study 26254445 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 510863
Study 26254445 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline recommended care
Number of subjects: 510863
Study 26254445 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital level variation in treatment
Number of subjects: 510863
Study 26254445 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio for hospitals' use of PCI
Number of subjects: 510863
Study 26254472 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree for serious infection diagnosis
Number of subjects: 8962
Study 26254576 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise programme for 6 months (OW-Trained)
Number of subjects: 19
Study 26254576 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 19
Study 26254576 — intervention group
Group type: EXPERIMENTAL
Intervention: OW-Trained
Number of subjects: 19
Study 26254576 — intervention group
Group type: EXPERIMENTAL
Intervention: OW-Untrained
Number of subjects: 19
Study 26254576 — intervention group
Group type: COMPARATOR
Intervention: Control and OW-Trained
Number of subjects: 19
Study 26254576 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 19
Study 26254812 — intervention group
Group type: EXPERIMENTAL
Intervention: MET-HIT2000AB4 sandwich strategy (postoperative chemotherapy, hyperfractionated craniospinal radiotherapy, and maintenance chemotherapy)
Number of subjects: 23
Study 26254812 — intervention group
Group type: COMPARATOR
Intervention: HIT'91 maintenance strategy (postoperative craniospinal radiotherapy, and maintenance chemotherapy)
Number of subjects: 23
Study 26254812 — intervention group
Group type: EXPERIMENTAL
Intervention: Large cell/anaplastic medulloblastoma
Number of subjects: 23
Study 26254812 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic medulloblastoma
Number of subjects: 23
Study 26254812 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoplastic medulloblastoma
Number of subjects: 23
Study 26254836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound findings categorized as cirrhosis
Number of subjects: 719
Study 26254836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound findings categorized as homogeneous
Number of subjects: 719
Study 26254836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound findings categorized as heterogeneous
Number of subjects: 719
Study 26254836 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound findings categorized as normal
Number of subjects: 719
Study 26254836 — intervention group
Group type: EXPERIMENTAL
Intervention: Early infection with Pseudomonas aeruginosa (<2 years old)
Number of subjects: 719
Study 26254836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid use
Number of subjects: 719
Study 26254836 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-related diabetes
Number of subjects: 719
Study 26255045 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of CRC (1 first degree relative)
Number of subjects: 14961
Study 26255045 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of CRC (≥2 first degree relatives)
Number of subjects: 14961
Study 26255045 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of CRC
Number of subjects: 14961
Study 26257082 — intervention group
Group type: EXPERIMENTAL
Intervention: PreImplantation Factor (PIF)
Number of subjects: 0